Head and neck squamous cell carcinoma (HNSCC) patients have a poor prognosis, with invasion and metastasis as major causes of mortality. The phosphatidylinositol 3-kinase (PI3K) pathway regulates a wide range of cellular processes crucial for tumorigenesis, and PIK3CA amplification and mutation are among the most common genetic alterations in human HNSCC. Compared with the well-documented roles of the PI3K pathway in cell growth and survival, the roles of the PI3K pathway in tumor invasion and metastasis have not been well delineated. We generated a PIK3CA genetically engineered mouse model (PIK3CA-GEMM) in which wild-type PIK3CA is overexpressed in head and neck epithelium. Although PIK3CA overexpression alone was not sufficient to initiate HNSCC formation, it significantly increased tumor susceptibility in an oral carcinogenesis mouse model. PIK3CA overexpression in mouse oral epithelium increased tumor invasiveness and metastasis by increasing epithelial-mesenchymal transition and by enriching a cancer stem cell phenotype in tumor epithelial cells. In addition to these epithelial alterations, we also observed marked inflammation in tumor stroma. AKT is a central signaling mediator of the PI3K pathway. However, molecular analysis suggested that progression of PIK3CA-driven HNSCC is facilitated by 3-phosphoinositide-dependent protein kinase (PDK1) and enhanced transforming growth factor β (TGFβ) signaling rather than by AKT. Examination of human HNSCC clinical samples revealed that both PIK3CA and PDK1 protein levels correlated with tumor progression, highlighting the significance of this pathway. In summary, our results offer significant insight into how PIK3CA overexpression drives HNSCC invasion and metastasis, providing a rationale for targeting PI3K/PDK1 and TGFβ signaling in advanced HNSCC patients with PIK3CA amplification.
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide, with 650 000 new cases and 350 000 deaths every year. 1 There are 55 000 new cases and over 15 000 deaths from HNSCC annually in the United States. 2 The most common etiological factors for HNSCC are tobacco exposure, alcohol and human papilloma virus infection. 3 Although tremendous efforts have been made to improve the treatment for HNSCC patients, HNSCC remains a lethal disease, with 5-year survival rates below 50%, a number that has not significantly changed in several decades. 2 Locoregional invasion, recurrence and metastasis are largely responsible for the poor prognosis of HNSCC patients. However, the underlying molecular mechanisms for HNSCC progression are still poorly understood.
The phosphatidylinositol 3-kinase (PI3K) signaling pathway is a key mediator of cell survival, growth and metabolism, and is commonly altered in many human malignancies, including HNSCC. [4] [5] [6] The PI3K family is comprised of three subclasses of lipid kinases. Class IA PI3K, composed of a heterodimer between a p110 catalytic subunit and a p85 regulatory subunit, has been intensively studied and demonstrated to be commonly altered in human cancers. 4 ,5 PI3K phosphorylates phosphotidylinositol-4,5, bisphosphate to phosphotidylinositol-3,4,5,trisphosphate, a reaction which is antagonized by the tumor-suppressor phosphatase and tensin homolog (PTEN). In turn, phosphotidylinositol-3,4,5, trisphosphate binds a subset of pleckstrin homology domaincontaining proteins, including AKT and 3-phosphoinositidedependent protein kinase (PDK1). AKT is activated by phosphorylation on serine 473 by the mTORC2 complex, and on threonine 308 by PDK1. Activated AKT directly regulates multiple downstream molecules, such as mTORC1 and p70-S6, to transduce the major downstream PI3K signal pathway. 4, 5 However, it has been shown that, in certain contexts, PI3K signaling and AKT activation can be uncoupled. [7] [8] [9] HNSCC cases exhibit PIK3CA amplification, and~10% harbor PIK3CA gain-of-function mutations. [4] [5] [6] [10] [11] [12] [13] Although several studies suggest PIK3CA alterations correlate with advanced HNSCC stage, 10, 14, 15 vascular invasion 16 and lymph node metastasis, 17 there are no in vivo studies that have elucidated the mechanisms by which PIK3CA alterations lead to HNSCC development and progression.
To address this, we generated an inducible head-and-neckspecific genetically engineered mouse model (GEMM), in which PIK3CA is overexpressed in head and neck epithelium. Our results showed that in this GEMM overexpression of PIK3CA alone resulted in head and neck epithelial hyperplasia but was not sufficient to initiate tumorigenesis. However, overexpression of PIK3CA significantly increased susceptibility to oral carcinogeninduced head and neck tumorigenesis. Strikingly, PIK3CA overexpression promoted HNSCC invasion and metastasis through epithelial-mesenchymal transition (EMT) and enrichment of putative head and neck cancer stem cells (CSCs). Further molecular studies showed that activation of PDK1 and enhanced transforming growth factor β (TGFβ) signaling play an important part in HNSCC progression. Our findings highlight the key role of PDK1 and TGFβ signaling in HNSCC invasion and metastasis, and suggest that targeting PDK1 and TGFβ signaling may be effective approaches to controlling HNSCC progression, particularly in patients with PIK3CA gene amplification.
RESULTS
Overexpression of PIK3CA in murine head and neck epithelia resulted in increased susceptibility to head and neck carcinogenesis Although PIK3CA amplification/mutation has been described in human HNSCC, little is known about its in vivo role during head and neck tumorigenesis. To this end, we developed an inducible, head-and-neck-specific PIK3CA genetically engineered mouse model (PIK3CA-GEMM) using previously published methods. 18 Briefly, the PIK3CA-GEMM consists a transactivator mouse line (K5. GLp65) and a target mouse line (tata.PIK3CA; Figure 1a ). In the transactivator line, the keratin 5 (K5) promoter is used to restrict expression of the GLp65 fusion protein to the basal layer of stratified epithelia (for example, buccal mucosa, tongue). GLp65 consists of a GAL4 DNA-binding domain, the NF-κB p65 transactivation domain and an RU486-inducible truncated progesterone receptor ligand-binding domain (ΔPR-LBD). The K5. GLp65 mice were bred to the tata.PIK3CA mice to generate the bigenic K5.GLp65/tataPIK3CA (hereafter referred to as PIK3CA- GEMM). The monogenic K5.GLp65 and tata.PIK3CA mouse lines were used as experimental controls. Starting at 4 week of age, mice were orally treated with RU486 dissolved in sesame oil. As shown in Figure 1b , upon RU486 application, the expression level of PIK3CA mRNA increased about 8-to 10-fold in the buccal mucusa and tongue tissues from the PIK3CA-GEMM compared with those from the control mice or the PIK3CA-GEMM without RU486 application. Correspondingly, the protein level of p110α (encoded by the PIK3CA gene) was also increased in PIK3CA-GEMM head and neck tissues upon RU486 application (Figure 1c) .
Buccal mucosa Tongue
After verifying induced expression of PIK3CA in the PIK3CA-GEMM head and neck epithelia following RU486 administration, we treated PIK3CA-GEMMs with oral RU486 (20 μg/mouse) twice weekly. Epithelial hyperplasia and carcinoma in situ with increased cell proliferation were observed in both buccal mucosa and tongue tissue as early as 6 months after initiation of treatment (Supplementary Figure 1) . However, these premalignant lesions failed to progress into squamous cell carcinomas (SCCs), suggesting that PIK3CA overexpression alone is not sufficient to induce HNSCC formation.
One of the major etiological factors of human HNSCC development is tobacco exposure. 3 To mimic this human situation and investigate the interaction between environmental factors and genetic susceptibility, we applied the 4-nitroquinoline 1 oxide (4NQO)-induced HNSCC carcinogenesis protocol to the PIK3CA-GEMM. 4NQO is a DNA adduct-forming agent widely used as a tobacco surrogate to induce HNSCC in mouse models. 19 As shown in Figure 2a , PIK3CA-GEMM and control mice were treated with RU486 applied orally twice weekly and with 4NQO added to drinking water (50 μg/ml) starting when the mice were 1-month Figure 2 . Overexpression of PIK3CA together with 4NQO treatment increases tumor susceptibility and promotes tumor invasion and metastasis of the 4NQO-induced HNSCC. (a) Schematics of the animal experiment. Starting at 1 month of age, PIK3CA-GEMMs and control mice were given 4NQO (50 μg/ml) in the drinking water for 16 weeks, and RU486 (20 μg/mouse) applied orally twice weekly until harvesting mice at 12 months. (b) Summary of tumor incidences in the PIK3CA-GEMMs and control mice. All mice underwent a biweekly full oral cavity examination, and any pathologic changes were documented. Tumor onset was significantly earlier for the PIK3CA-GEMMs old. Mice were exposed to 4NQO for 16 weeks, and received RU486 through the end of the 12-month experiment. PIK3CA overexpression significantly enhanced susceptibility to 4NQO-induced head and neck carcinogenesis (Figure 2b ). By 5 to 6 months of age, 39% of PIK3CA-GEMMs developed HNSCC, compared with only 8% of control mice (P o 0.01). By 10-12 months, all 4NQO-treated control and PIK3CA-GEMM mice developed HNSCC. The authentication of the PIK3CA tumors was validated by transgene-specific genotyping PCR (Supplementary Figure 2) . By the time of tumor harvest, there were no differences in the general health and nutritional status (for example, activity or body weight) between the control mice and the PIK3CA-GEMMs.
PIK3CA-GEMM

Overexpression of PIK3CA in murine head and neck epithelia promotes tumor invasion and metastasis It was immediately clear that tumors from PIK3CA-GEMMs and those from control mice differed in gross appearance: although most control tumors were papillomatous, tumors from the PIK3CA-GEMMs were flat (Figure 2c) . Histologically, the majority of the control tumors had an out-growth pattern with intact basement membranes (left panels of Figure 2d and Supplementary Figure 3) , whereas tumors from the PIK3CA-GEMMs predominantly had a down-growth pattern with broken basement membranes and invasion into muscle (right panels of Figure 2d and Supplementary Figure 3) . Although over 60% of the control tumors were well-differentiated or carcinoma in situ, over 50% of the PIK3CA-overexpressing tumors were poorly differentiated as confirmed by a head and neck pathologist (Figures 2d and e and Supplementary Figure 3) . Notably, metastases were observed in~40% of the PIK3CA-GEMMs (regional lymph node or lung metastases) compared with no metastases in control mice (Figure 2f ). These data showed that overexpression of PIK3CA promoted 4NQO-induced HNSCC progression, particularly tumor invasion and metastasis.
PIK3CA overexpression induced de-differentiation, EMT and enriched CSC properties The poorly differentiated tumor histology observed in the PIK3CA- differentiation markers. As shown in Figure 3a , while Keratin 1 (K1, green) was still retained in the control tumors, marking welldifferentiated SCC, it was lost in the PIK3CA-GEMM tumors. In contrast, Keratin 8 (K8, red), seen in poorly differentiated SCC, was rarely expressed in control tumors, whereas it was highly expressed in tumors from PIK3CA-GEMMs. This differential keratin expression was further confirmed by K1 and K8 mRNA expression quantified by quantitative PCR (qPCR; Figure 3b ). In addition to these findings, EMT was observed in the PIK3CA-GEMM tumors. As shown in Figure 3c , in contrast to the universal expression of the epithelial marker E-cadherin (green) in control tumors, E-cadherin expression was lost in the PIK3CA-GEMM tumors. Conversely, the mesenchymal marker Vimentin (red) was expressed only in the stroma of the control tumors, but was expressed in the epithelium of PIK3CA-GEMM tumors, suggesting that EMT had taken place. This was further confirmed by qPCR showing decreased E-cadharin and increased Vimentin mRNA expression in the PIK3CA-GEMM tumors (Figure 3d ). Last, relative to controls, the PIK3CA-GEMM tumors showed significantly increased expression of several transcription factors regulating EMT, including Twist1, Zeb1, Zeb2 and Snail1 (Figure 3e) . Thus, the PIK3CA-GEMM tumors exhibited both histopathological and molecular signature of EMT.
It has been shown that de-differentiation and EMT correlate with enhanced CSC/progenitor activity. 20 We thus examined putative CSC markers of HNSCC by qPCR. As shown in Figure 3f , overexpression of PIK3CA significantly increased the mRNA expression of CD44 and CD166, and reduced the expression of CD24, all of which indicate an enhanced CSC phenotype. This result is further supported by increased mRNA expression of embronic stem cell markers Nanog, Oct4 and EZH2. Interestingly, increased expression of Wnt5a, which is implicated in migration/ invasion, was also found in the PIK3CA-GEMM tumors (Figure 3f ).
PIK3CA-GEMM tumors have increased PDK1 expression and activation
To investigate the molecular mechanisms of PIK3CA-driven HNSCC progression, we examined several key molecules in the PI3K pathway. It has been shown that the change of mRNA expression ratio between AKT1 and AKT2 regulates EMT in breast cancer cells. 21 However, there were no significant changes of mRNA expression of AKT1, AKT2, PDK1 or PTEN in the PIK3CA-GEMM tumors compared with control tumors (Figure 4a ). AKT1 and AKT2 protein levels were similar between control and PIK3CA-GEMM tumors. However, PDK1 protein levels were increased in PIK3CA-GEMM tumors (Supplementary Figure 4) . We then examined AKT and PDK1 protein activation by western blotting. Surprisingly, we did not detect significant differences in AKT phosphorylation at either Ser473 or Thr308 between the control and the PIK3CA-GEMM tumors. However, PDK1 activation by phosphorylation at Ser241 was significantly enhanced in PIK3CA-GEMM tumors (Figure 4b) . Similarly, immunohistochemistry (IHC) staining showed an increase of total PDK1 protein in the PIK3CA-GEMM tumors (Figure 4c ). These findings were unexpected and suggested that PDK1 may mediate oncogenic signaling in PIK3CA-driven HNSCC progression. Last, we examined several molecules that are commonly altered in human HNSCCs. 4NQO exposure causes the formation of DNA adducts, resulting in mutations. 19 We first examined two oncogenes that are commonly mutated in HNSCC, that is, Ras and PIK3CA. We sequenced eight PIK3CA-GEMM tumors and eight control tumors for mutations at codons 12, 13 and 61 of the K-ras and H-ras genes, and exons 9 and 20 of the PIK3CA gene. The only mutation we found was a G to A point mutation in codon 12 of mouse K-ras gene, which changes glutamic acid to aspartic acid (Supplementary Figure 5) . This mutation was found only in one control tumor. We then examined the mRNA levels of p16, EGFR, Stat3, CyclinD1, K-ras, H-ras and N-ras in PIK3CA-GEMM and control tumors. We found increased Stat3 and decreased p16 mRNA in the PIK3CA-GEMM tumors compared with control tumors (Figure 4d ).
To further examine whether PDK1 is involved in the tumor progression of the PIK3CA-GEMM mice, we cultured primary tumor cells from both PIK3CA-GEMM tumors (CU110 cells) and control tumors (CUCON cells). As shown in the Supplementary Figure 6A , consistent with the EMT changes in the tumor tissues, CU110 cells were more spindle-like, whereas CUCON cells were more round and epithelial-like. Overexpression of p110α was observed in the CU110 cells compared with that in CUCON cells (Figure 6e , left panel). We then stablely knocked down PDK1 in the CU110 cells (CU110-shPDK1), along with CU110 cells with a scramble insert (CU110-SCR) as a control (Figure 4e and Supplementary Figure 6B) . Knocking down PDK1 in the CU110 cells increased E-cadherin expression and decreased Vimention expression (Figure 4e ), but had no effects on phosphorylations of Smad2 or Smad3 (Supplementary Figure 6B) . In addition, knocking down PDK1 (CU110-shPDK1) significantly reduced cell proliferation compared with the control cells (CU110-SCR; Figure 4f ). Moreover, knocking down PDK1 in the CU110 cells moderately attenuated cell migration (Figure 4g ) and invasion (Figure 4h ) abilities. These data suggested that PDK1 contributed to the tumor progression phenotypes observed in the PIK3CA overexpression HNSCCs.
PIK3CA overexpression led to increased inflammation in HNSCC tumor stroma In addition to the de-differentiation and EMT changes in the PIK3CA-GEMM tumor cells, we observed numerous infiltrated leukocytes in the stroma of the PIK3CA-GEMM tumors on histological sections examined by hematoxylin and eosin staining (Supplementary Figure 7) and IHC with CD45 ( Figure 5a ). We then examined subtypes of infiltrated leukocytes using IHC. Tumorassociated macrophages are stained by F4/80 antibody, and myeloid-derived suppressor cells in a tumor microenvironment are stained by granulocyte markers Gr1 and CD11b. 22 Both cell types were increased in PIK3CA-GEMM tumors compared with control tumors (Figure 5a ). Last, we evaluated which cancerassociated inflammatory cytokines were upregulated in PIK3CA-GEMM tumors. Among the 15 inflammatory chemokines/receptors we evaluated, mRNA levels of CCL3, CCR7, CXCL12 and CXCR4 were all significantly increased in the PIK3CA-GEMM tumors compared with the control tumors (Figure 5b ).
PIK3CA-GEMM tumors have increased TGFβ1 ligand, and increased Smad3 expression and activation
The EMT change in tumor cells and the enhanced leukocyte infiltration in PIK3CA-GEMM tumors are similar to what we observed previously in HNSCC mouse models with aberrant TGFβ signaling. 18, 23, 24 This prompted us to further investigate whether TGFβ signaling contributes to PIK3CA-driven HNSCC progression. We first used quantitative reverse transcription-PCR (qRT-PCR) to examine several TGFβ signaling pathway molecules known to be altered in human cancers. We found that mRNA levels of TGFβ1 and Smad3 were significantly higher in PIK3CA-GEMM tumor tissues than in control tumor tissues (Figure 6a ). TGFβ1 protein level was also increased in the PIK3CA-GEMM tumor tissues, as determined by ELISA (Figure 6b) . We then performed double IF of Smad3 and the epithelial marker E-cadherin. As shown in Figure 6c , the Smad3-positive area was inversely correlated with E-cadherin-positive staining, suggesting that Smad3 may contribute to the EMT changes in the PIK3CA-GEMM tumors. Increased phosphorylation of Smad3 in the PIK3CA-GEMM tumors compared with the control tumor tissues was also observed through western blot analysis (Figure 6d) .
To further assess the role of TGFβ signaling in mediating the tumor-promoting effects of PIK3CA overexpression, we created CU110 cells in which the PIK3CA gene was knocked down (CU110-shPIK3CA), along with CU110 cells with a scramble insert (CU110-SCR) as a control (Figure 6e, right panel) . To examine the effect of PIK3CA overexpression or knockdown on TGFβ pathway in the cultured HNSCC cells to check whether PIK3CA-mediated regulation of TGFβ pathway is cell autonomous in cancer cells, we compared TGFβ1 mRNA levels in CUCON, CU110, CU110-shPIK3CA and CU110-SCR cells. As shown in Figure 6f , TGFβ mRNA levels in the CU110 cells were about four times than that in the CUCON cells. Conversely, knocking down PIK3CA significantly reduced TGFβ1 mRNA levels in CU110-shPIK3CA cells compared with the CU110-SCR cells, suggesting that the PIK3CA-mediated regulation of TGFβ pathway is cell autonomous in cancer cells. Last, we treated the PIK3CA-overexpressing CU110 cells with a TGFβ type I receptor kinase inhibitor, LY2157299, to address the contribution of TGFβ pathway to the PIK3CA-driven HNSCC progression. Treatment with LY2157288 effectively reduced Smad2 and Smad3 phosphorylation, indicating the effectiveness of the inhibition of the TGFβ signaling pathway (Figure 6g) . Following the treatment, Figure 6C) , indicating that the TGFβ pathway contributes to migration and invasion of PIK3CA-driven HNSCC tumorigenesis.
PIK3CA and PDK1 are associated with progression in human HNSCC To address the clinical relevance of our results from the PIK3CA-GEMM, we examined PIK3CA, PDK1 and pAKT expression levels in primary human HNSCC samples, case-matched adjacent mucosa and metastatic lesions, compared with normal oropharyngeal samples from patients with sleep apnea as controls. We first performed qRT-PCR to measure PIK3CA mRNA levels. Compared with normal controls, PIK3CA mRNA was increased in both adjacent mucosa and HNSCC samples (Figure 7a ). Interestingly, increased PIK3CA expression positively correlated with reduced tumor differentiation and increased lymph node metastasis ( Figure 7a ). We then carried out IHC staining of p110α, PDK1 and pAKT. Figures 7b summarizes the percentage of cases with immunostaining ⩾ 2+ in HNSCC tumors and metastases. Consistent with PIK3CA qRT-PCR results, we found increased p110α immunostaining both in poorly differentiated HNSCCs and in metastases (Figures 7b and c) . Interestingly, PDK1 expression positively correlated with PIK3CA expression and advanced disease (Figure 7b and c) . However, AKT activation showed the opposite pattern, and demonstrated reduced expression in poorly differentiated tumors and metastases compared with early-stage lesions. These data from human tissue sample support our mouse model data that PIK3CA-driven HNSCC progression is predominantly mediated through PDK1, but not through AKT.
DISCUSSION
Previous mouse models were generated by knocking in PIK3CA mutant H1047 into different tissue contexts. [25] [26] [27] [28] [29] However, somatic mutations of PIK3CA are infrequent (~10%) compared with PIK3CA gene amplification (~40%) in HNSCC patients. 4, 5 Thus, our PIK3CA-GEMM, in which the wild-type PIK3CA is overexpressed specifically in murine head and neck epithelium, more closely mimics the majority of human HNSCC patients. As this transgene can be induced in a spatio-temporal manner, our model is an ideal platform to assess the role of PIK3CA overexpression at each stage of HNSCC tumorigenesis. This also represents the first GEMM in head and neck tissue for studying the in vivo role of PIK3CA.
In the PIK3CA-GEMM, we found that PIK3CA overexpression alone is not sufficient to initiate tumor formation in head and neck tissue. This is in contrast to the results of tumor formation in breast and lung cancer mouse models. [25] [26] [27] One explanation is that previous mouse models were based on gene mutations compared with our model, which is based on gene overexpression; these two types of gene alterations may play distinct roles in tumorigenesis. The other possibility is that PIK3CA may have a context-specific role in tumorigenesis. For example, the same mutant PIK3CA-H1047 that causes spontaneous breast and lung tumor formation is not sufficient to initiate tumor formation in ovarian or colon tissues unless coupled with either a PTEN or APC deletion. 28, 29 Our data suggest that PIK3CA overexpression may not initiate Compared with the well-documented mitogenic signaling of PI3K in cell growth and survival, the role of PI3K in tumor invasion and metastasis has not been well delineated. In a subset of aggressive breast cancer, which exhibits EMT and CSC characteristics, the authors found the mutation rate of PIK3CA reached nearly 50%, significantly higher than in any other types of breast cancer. 30 Knocking in the PIK3CA mutant into a breast cancer cell line also resulted in an EMT phenotype. 31 In line with these data, our PIK3CA-GEMM provides the first in vivo evidence that PIK3CA alteration is able to drive tumor progression at least partially through enriched EMT and CSC characteristics, which may be responsible for the invasive and metastatic phenotype observed in the PIK3CA-GEMM.
AKT is largely regarded as the dominant mediator of oncogenic PI3K signaling. 4 However, studies suggest that the link between PI3K and AKT can be uncoupled. 7, 8, 32, 33 Recent reports showed that AKT can directly phosphorylate Twist1 to promote EMT, 34 and that the ratio of AKT1 and AKT2 and its regulated microRNAs are responsible for EMT and CSCs. 21 However, we found no differences in AKT activation or expression of AKT isoforms between control and PIK3CA-GEMM tumors. Lack of AKT activation has also been observed in subset of PIK3CA-mutated breast cancer, 8 PTEN-null lung cancers 35 and BRAF-initiated melanoma. 9 AKT activation can be detected in mouse models as early as preneoplastic lesions upon either 4NQO 36 or NNK treatment, 37 and AKT activation in the oral cavity can initiate benign tumor formation. However, it fails to promote tumor progression unless combined with p53 loss, 38 suggesting that AKT activation may be involved in early events in HNSCC carcinogenesis, but not in tumor progression. In some breast cancers with PIK3CA mutations, PDK1, but not AKT, is activated. 8 Similarly, our results suggest that PDK1, rather than AKT, facilitates progression of PI3K-driven HNSCC, which raises the possibility of PDK1 as a therapeutic target in HNSCC patients with PIK3CA alterations.
PDK1 is a serine/threonine protein kinase that phosphorylates members of the AGC kinase superfamily, including AKT, and is implicated in cell proliferation, survival and metabolism. 39 Interestingly, PDK1 has been shown to regulate cell migration but not proliferation in lymphocytes, 40 and to promote EMT in cardiac development. 41 Compared with the extensive research into AKT, less is known about the role of PDK1 in human cancers. Overexpression of PDK1 has been reported in several human cancers, [42] [43] [44] and correlates with disease progression in patients with pancreatic cancer or melanoma. 43, 44 Interestingly, PDK1 is required for Kras-driven pancreatic cancer in murine models but not for the Kras-driven lung cancer, suggesting a context-specific role of PDK1. 45 In HNSCC, PDK1 has been shown to mediate G-protein-coupled receptor and epidermal growth factor receptor (EGFR) cross-talk as well as cell growth, both in vitro and in vivo. 46 It has become evident recently that the role of PDK1 in physiological and pathological conditions is not limited to AKT activation; it may also evoke other signaling for tumorigenesis. For example, PDK1 has been shown to activate SGK3 in a PI3K-dependent, AKT-independent manner in breast cancer.
8 PDK1 can also directly activate PLCγ1 to mediate cancer cell invasion. 47 Moreover, PDK1 directly phosphorylates polo-like kinase 1 to induce an embryonic stem cell-like gene signature associated with aggressive tumor behaviors and CSC self-renewal. 48 Further investigation on the downstream molecular mechanisms underlying PI3K/PDK1 signaling in the PIK3CA-GEMM will provide important insights into PIK3CA-driven HNSCC progression and identify novel therapeutic targets to control HNSCC progression.
The downstream mechanisms of PI3K/PDK1 in HNSCC invasion and metastasis are largely unknown. In this study, we found that the TGFβ1 ligand and its downstream mediator Smad3 are overexpressed in PIK3CA-GEMM tumor tissues. The positive correlation between PIK3CA and TGFβ1 levels was further detected in both PIK3CA-overexpressing tumor cells and PIK3CA-knockdown tumor cells, suggesting that the PIK3CA-mediated regulation of TGFβ pathway is cell autonomous. The contribution of TGFβ pathway to mediate migration and invasion of PIK3CA-overexpressing tumor cells was validated by treating these cells with a TGFβ pathway inhibitor. Cross talk between PI3K and TGFβ signaling can occur at multiple levels. 49 For example, PI3K is able to mediate TGFβ-receptor-initiated intracellular signaling. 50 In addition, PI3K can antagonize TGF-β-induced cytostasis and cause the shift in TGFβ signaling to tumor progression. 49 However, prior reports on PI3K and TGFβ interplay were almost exclusively related to AKT signaling. 49 Thus, it remains unclear how PI3K/PDK1 interacts with TGFβ/Smad3 signaling during HNSCC progression.
Currently, the only Food and Drug Administration-approved targeted therapy for HNSCC is EGFR inhibitors. 51 Targeting the PI3K pathway represents a promising new strategy for treating HNSCC. The role of PDK1 in mediating invasion and metastasis of PIK3CA-driven HNSCC suggests it may be useful as a therapeutic target. Targeting PDK1 using either genetic approaches or pharmaceutical inhibitors has been shown to inhibit CSC selfrenewal and metastasis. 44, 48, 52 In one pre-clinical study on HNSCC, PDK1 inhibition showed anti-tumor effects either by itself or in combination with EGFR inhibition. 46 Thus, targeting PIK3CA or PDK1 presents an important new avenue for HNSCC treatment. Targeting TGFβ as anti-cancer therapy has been evaluated for a decade in multiple cancers. 53 However, it remains unclear how it may best be used and such therapies are highly stage-and patient-specific. The possible synergistic role of overactivated PI3K and TGFβ signaling in HNSCC progression demonstrated in this study has prompted testing of combination therapy. If proven effective in pre-clinical trials with PIK3CA-GEMM, this combination therapy will be immediately translated into clinical trials for treating advanced HNSCC patients who have PIK3CA alterations.
In summary, we report a GEMM in which the PIK3CA is overexpressed in head and neck epithelia. Although overexpression of PIK3CA alone is not sufficient to initiate HNSCC formation, it significantly increased the susceptibility to the 4NQO-induced HNSCC carcinogenesis. More importantly, PIK3CA overexpression promotes EMT and CSC properties and drives tumor invasion and metastasis, which is likely mediated by increased PDK1 expression and activation, and subsequently increased TGFβ1 ligand and Smad3 expression and activation. Our study lays the foundation for future investigations into the mechanism of PDK1 and its interplay with TGFβ signaling in PIK3CA-driven HNSCC tumorigenesis. Moreover, it suggests that therapeutic targeting of PDK1 and/or TGFβ signaling may effectively control HNSCC progression, particularly in patients with PIK3CA amplification.
MATERIALS AND METHODS
Generation and characterization of the inducible head-and-neckspecific PIK3CA GEMM All animal experiments were performed in accordance with protocols approved by the Institutional Animal Cancer and Use Committees of the Oregon Health and Science University (OHSU) and University of Colorado School of Medicine. The plasmid containing full-length cDNA of PIK3CA (pcDNA3.1-PIK3CA) was obtained from Addgene (Cambridge, MA, USA) under the material transfer agreement agreement. The PIK3CA fragment was subcloned into the target vector (ptata.A) using the XhoI site (Supplementary Figure 8a) . A 3.5-kb HindIII/KpnI fragment including Gal4-binding sites, minimal tata promoter and the PIK3CA cDNA was microinjected into the pronucleus of single-cell embryo by the transgenic mouse core facility at OHSU. The embryos were implanted into pseudo-pregnant females and allowed to develop to term. PCR genotyping was performed at the 3 weeks of age using genomic DNA isolated from tail biopsies. Three lines (#5840, #5446, #5703) transmitted the transgene through their germline and was called tata.PIK3CA mouse line thereafter (Supplementary Figure 8b) . The transgene-specific primers covering hemagglutinin tag were designed, along the upstream sequence. The primers used to detect the ptata.PIK3CA transgene were: forward: 5′-TGAGCAAGAGGCTTTGGAGT-3′ and reverse: 5′-TGCATTCTAGT TGTGGTTT-3′.
The target mouse line tata.PIK3CA was then bred to the transactivator mouse line, K5.GLp65, which was developed previously. 18 The resulting bigenic mouse line K5.GLp65/tata.PIK3CA is hereafter referred to as PIK3CA-GEMM. The PIK3CA-GEMMs were selected by using genotyping primers specific for GLp65 (forward: 5′-TGTCAAGGTCTTCTCGAGGA-3′; PIK3CA in head and neck cancer progression L Du et al reverse: 5′-GGCCATACACTTGAGTGACA-3′), and the same primers that were used for detection of the PIK3CA transgene (above).
All mouse experiments were performed in a C57BL/6 background. Adult bigenic K5.GLp65/tata.PIK3CA and monogenic K5.GLp65, tata.PIK3CA and non-transgenic mice (around 1-month-old) were treated with RU486 for PIK3CA gene induction and with the rodent oral carcinogen, 4NQO (Sigma, St Louis, MO, USA). For the transgene induction, 100 μl of RU486, dissolved in sesame oil (0.2 μg/ml), was applied in the oral cavity of mouse to induce either acute or sustained PIK3CA transgene expression as described previously. 18 For the oral carcinogenesis experiment, 4NQO (Sigma) was prepared weekly in propylene glycol at a concentration of 5 mg/ml, and was placed into drinking water in a final concentration of 50 μg/ml. The water was changed once weekly, and was given to mice for 16 weeks. The general health condition of mice was monitored twice weekly, and their body weight was measured once weekly. Mice were given softened food when there were signs of food-intake difficulty, or decreased body weight. At the end of animal experiment, mice were euthanized. Buccal mucosa, tongue, lymph node and lung tissues were harvested for histological analysis and immunostaining.
Patients
The clinical study protocol was approved by the Institutional Review Boardapproved of OHSU, and written informed consent was obtained from all participants before sample collection. HNSCC and case-matched adjacent tissue samples were surgically resected from consenting patients at the Departments of Otolaryngology and Dermatology of OHSU. Tissues examined in this study include a total of 74 HNSCCs (26 SCCs of tongue, 19 SCCs of oral cavity, 3 SCCs of nasal pharynx, 7 SCCs of oropharynx, 7 SCCs of hypopharynx, 12 SCCs of larynx) and case-matched tissues adjacent to tumors, and 24 cases of lymph node metastases. A total of 12 normal oropharyngeal samples from sleep apnea patients were used as normal controls.
Histology and immunostaining
Tissues were fixed in 10% neutral buffered formalin, embedded in paraffin and sectioned to 5-μm thickness. Sections were stained with hematoxylin and eosin and examined for the presence of hyperplasia, dysplasia, papillomas, carcinomas and metastases. Tumor pathology and metastasis were examined by at least two investigators and confirmed by the head and neck cancer pathologist (SS). Quantitation of IHC staining of human p110α, pAKT and PDK1 was performed by two independent investigators using methods described previously. 54 Double immunofluorescence was performed as previously described. 24 Incubation with primary antibodies was as follows: Keratin 1 (K1; Convance Princeton, NJ, USA, PRB-165 P), K8 (Fitzgerald, Acton, MA, USA, 20 R-CP004), Ecadherin (Cell Signaling, Danvers, MA, USA, #3195), Vimentin (BD Pharmingen, San Jose, CA, USA, RV202), Smad3 (Novus, Littleton, CO, USA, 378611). Immunohistochemistry was performed as described previously. 24 Incubation with primary antibodies was as followings: PDK1 (Abcam, Cambridge, MA, USA, ab52893), CD45 (eBioscience, San Diego, CA, USA, 14-0451), F4/80 (Serotec, Raleigh, NC, USA, MCA497GA), Gr1 (BD Pharmingen, 550291), CD11b (BD Pharmingen, 550282), p110α (Cell Signaling, #4249), Ki67 (Abcam, ab16667) and pAKT Ser473 (Cell Signaling, #3787). Slides were examined with a Leica microscope, and images were taken using the Q Capture Pro software (Q imaging, Surrey, BC, USA).
DNA sequencing, RNA isolation and qRT-PCR Genomic DNA isolation from mouse tumor tissues was performed as described previously. 23 Exon 1 and exon 2 of mouse H-ras, or K-ras, and exon 9 and exon 20 of mouse PIK3CA were amplified by PCR and sequenced using the sequences listed in Supplementary Table 1 . RNA isolation and cDNA synthesis were performed as described previously. 24 cDNAs were subjected to qRT-PCR using either the SYBR mix (Bio-Rad, Hercules, CA, USA) or the TaqMan Assays-on-Demand probes (Applied Biosystems, Foster City, CA, USA). qRT-PCR was run on the CFX connect qPCR machine (Bio-Rad). β-Actin was used as an internal control. Primer sequences for mouse SYBR qRT-PCR assay are listed in Supplementary  Table 2 . Primer sequences for human PIK3CA qRT-PCR are: forward-5′-ACC TGAATAGGCAAGTCGAGGCAA-3′, reverse-5′-ACAGAAAGCCCTGTAGAGCAT CCA-3′. Each sample was examined in triplicate. The relative RNA expression levels were determined by normalizing to the internal control, the values of which were calculated using the comparative Ct method.
Protein analysis
Whole head and neck tissues and tumors tissues were lysed using a homogenizer (Pro Scientific, Oxford, CT, USA) in lysis buffer (Roche, Indianapolis, IN, USA) containing a pellet of protease inhibitor cocktail. Protein concentration was measured using Pierce 660 nm protein assay reagent (Thermo, Waltham, MA, USA), and 40 μg of protein lysates were analyzed using the standard western blot protocol we have described previously. 37 Blots were incubated with primary antibodies at 4°C overnight and secondary antibodies for 1 h at room temperature. Western blots were imaged by ECL (Bio-Rad) and normalized with respect to GAPDH (Cell Signaling, #5174) expression. The primary antibodies were used as follows and purchased from Cell Signaling: p110α (#4255), PDK1 (#3438), pPDK1
Ser241 (#3061), pAKT Ser473 (#4058), pAKT Thr308 (#9275), AKT1 (#2938), AKT2 (#4057), pSmad2 ser465/467 (#3101) and pSmad3 ser423/425 (#9520). TGFβ1 ELISA was performed as described previously using the R&D Systems kit (R&D Systems, Minneapolis, MN, USA). 18 Cell culture Cells were cultured from either a 4NQO-induced control tongue SCC (CUCON) or a 4NQO-induced PIK3CA-GEMM tongue SCC (CU110). Tumor tissues were minced with blade, and digested in 0.35% collagenase (Gibco, Carlsbad, CA, USA) followed by two rounds of 1% trypsin digestion at 37°C. Single cells were obtained through a cell strainer (70 mm nylon, BD Biosciences, Franklin lakes, NJ, USA), and plated at 1×10 5 /ml in 10 cm dishes. Cells were cultured in DMEM+10% FBS and 100 U/ml penicillin/streptomycin (Gibco). The authentication of the cultured cells was validated by the transgene-specific genotyping PCR (Supplementary Figure 2) . Knockdown experiment. PIK3CA or PDK1 knockdown was achieved using a lentiviral-based shPIK3CA or shPDK1 purchased from Sigma (MISSION shRNA). TRCN0000361413 or TRCN0000361331 was used for mouse PIK3CA or PDK1 Knockdown, respectively, and SHC002 as a scramble control.
Cell Proliferation assay. Cells were seeded into 24-well plates as 1 × 10 5 cells/ well, and were treated with 0-80 μM LY2157299 (MedKoo Biosciences, Chapel hill, NC, USA) for 48 h. The cell proliferation was determined by using Vi-cell XR cell viability analyzer (Beckman Coulter, Brea, CA, USA). For the cell proliferation assay in CU110-shPDK1 and CU110-SCR cells, the assay was performed using cell counting kit 8 (Dojindo Molecular Technologies, Rockville, MD, USA).
Migration and Invasion assay. The migration and invasion assays were performed using CytoSelect 24-well wound healing assay kit (Cell Biolabs, San Diego, CA, USA) and QCM ECMatrix cell invasion assay kit (EMD Millipore, Billerica, MA, USA). Three individual experiments were performed for each assay.
Statistical analysis
Statistical analysis for all qPCR data was performed using a two-sample equal variance and two-tailed Student's t-test. All of the above statistical analyses were performed using Prism4 (GraphPad, La Jolla, CA, USA). A P-value of less than 0.05 is considered statistically significant.
